Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: T-DM1|DRUG: Trastuzumab|DRUG: Lapatinib|DRUG: Abraxane|DRUG: Paclitaxel|DRUG: Pertuzumab
Sponsor: The Methodist Hospital Research Institute
Collaborators: Celgene Corporation|Novartis